Monthly Archives: October 2010
Cancer Testing Times: One Thing the UK Will Not Be Cutting
Buried among the savage, £83 billion-worth of cuts announced by the UK coalition government’s controversial Comprehensive Spending Review last week was confirmation that the Department of Health would not be taking forward the previous government’s pledge to introduce a one-week target for cancer testing.
Under the Labour government, the time that it took for a patient [...]
Posted in Europe, Global, Guest Blog Tagged Cancer, diagnostics, health economics, Oncology, UK Leave a comment
Pharma Gets the ProPublica Treatment
Alternative news organization and media allies investigate the industry’s payments to doctors—launching a fresh assault on the ethical status quo.
By Walter Armstrong
Last week, Big Pharma’s practice of paying doctors to do medical education, promote its products, or both was the focus of a multimedia blitz launched by ProPublica in collaboration with National Public Radio, the [...]
Posted in FDA, Legal, Medical Education, Meetings Tagged compliance, doctor payments, ethics, Medical Education, Pharma, transparency 6 Comments
Understanding Serious Adverse Events Takes Serious Cooperation
What if the technology is at hand to prevent adverse reactions to medicines before they start?
The International Serious Adverse Events Consortium (iSAEC) came together in 2007 to research the cause of certain drug-induced serious adverse reactions, posing the question, “What if the identification of risk for adverse events were not a random development, but instead [...]

Brazil Profile: Latin America's Giant Repositions for Pharma Growth